Venture Capital Firms Engineered Federal Medical AI Policy From Inside

Lobbying filings, FDA press announcements, and trade association records document a coordinated campaign by VC-backed medical AI companies to simultaneously shape the agencies that approve their...

The Food and Drug Administration has publicly proposed creating direct contracting relationships with venture capital firms — the same firms whose portfolio companies the FDA is responsible for regulating. That single documented fact, drawn from an FDA press announcement archived at fda.gov, is the structural core of a broader influence campaign now visible in federal lobbying disclosures, trade association policy platforms, and pending legislation on Capitol Hill.

The financial logic begins with a bottleneck. Despite the FDA having cleared hundreds of AI-enabled medical imaging algorithms through its 510(k) and De Novo pathways, only two Category 1 CPT reimbursement codes exist for newer AI tools under Medicare, according to Radiology Business coverage cited in Legis1 Newsroom reporting on Aidoc's federal lobbying campaign. FDA clearance, in other words, does not guarantee a dollar of federal revenue. The legislative and regulatory prize is CMS reimbursement policy — and two active bipartisan bills, the Health Tech Investment Act and the Ensuring Access to Critical Breakthrough Products Act, are both aimed precisely at that prize. The National Venture Capital Association, the industry's primary trade body, publicly endorses advancing legislation consistent with both bills' frameworks on its healthcare innovation policy page at nvca.org.

Aidoc, an Israeli-founded, VC-backed radiology AI company with multiple FDA clearances, retained the lobbying firm DLA Piper LLP to advance that agenda in Washington. DLA Piper manages more than $80 million in annual lobbying contracts across healthcare and technology sectors, according to Legis1 Newsroom. The specific dollar value of the DLA Piper–Aidoc contract is not disclosed in available source materials; it would appear on Lobbying Disclosure Act filings under Aidoc's name at lda.senate.gov. What the filings do confirm, per Legis1 Newsroom, is that DLA Piper's advocacy on Aidoc's behalf targets FDA pathway modernization and the creation of new Medicare reimbursement streams for AI radiology tools. If either pending bill passes, Aidoc would stand to access CMS payment streams potentially worth tens to hundreds of millions of dollars annually, depending on hospital utilization rates across the United States.

A second company, 4D Medical, which makes novel lung imaging technology, spent $650,000 on federal lobbying across 23 quarterly filings from 2020 through 2025, according to OpenLobby.us. Its registered lobbyists at Tremont Strategies Group — formerly ADS Ventures — include Liesl Grebenstein Sheehan, David Garriepy, Alexandra Eby, and Malia Ching, all named in LDA filings. Their disclosed issue areas are Defense, Health Issues, Veterans, and Budget/Appropriations, with filing language describing 'education and advocacy around health issues associated with burn pits.' The strategic positioning is direct: the PACT Act of 2022 created mandatory VA healthcare coverage for millions of veterans with toxic exposure conditions, opening a new structured federal payer pool. A company whose technology is designated as a covered diagnostic for burn pit-related pulmonary conditions would access that revenue stream with minimal competitive pressure. The prior government employment history of the four named lobbyists — a standard indicator of revolving-door advantage — is not established in available public records and would require cross-referencing with OPM personnel data and prior LDA filings.

The FDA's proposed contracting model is the most structurally significant element of this campaign. The agency's own press announcement states that it is 'seeking input on a proposed contract model that creates direct relationships with qualified venture capital firms,' on the stated rationale that 'many breakthrough technologies relevant to its public health mission are being developed by firms within venture capital portfolios.' The conflict that creates is explicit in the structure: a VC firm holding an FDA contract to supply AI regulatory technology would simultaneously hold financial stakes in companies seeking FDA approval for medical AI products. The agency that awards the contract would also regulate the contractor's portfolio companies. The FDA announcement itself acknowledges that adjacent small business contracting programs 'have faced concerns about misuse,' without specifying what oversight mechanisms the new model would impose. No VC firms are named in the announcement as having been consulted; identifying which firms engaged with this request for information would require a FOIA request to FDA.

The NVCA functions as the coordination layer connecting these individual company campaigns into a unified policy vector. Its published healthcare platform calls for clear FDA guidance for AI medical devices, streamlined approval and reimbursement pathways, AI-ready standards for federally funded research data, and direct VC-FDA contracting — positions that map precisely onto the FDA proposal, the two pending bills, and the CPT code expansion Aidoc's lobbyists are pursuing. NVCA's own LDA filings, its total annual lobbying expenditures, and the specific congressional offices it has contacted are not reproduced in available source materials and are public records at lda.senate.gov. The member firms with the largest medical AI portfolio exposure — and therefore the strongest financial motivation to drive NVCA's positions — are not identified in the association's public disclosures.

The peer-reviewed record provides historical context. A study published in JAMA Internal Medicine, indexed at PMC under accession PMC7054854, found that the pharmaceutical and health product industry was the largest single lobbying spender of any U.S. sector from 1999 through 2018, with documented influence on specific healthcare legislation. Medical AI lobbying is still nascent by comparison but is following the identical structural blueprint: trade association coordination, major retained lobbying firms, targeted legislative vehicles, and regulatory agency engagement. The question the public record cannot yet answer is how much of the legislative text in the Health Tech Investment Act and the Ensuring Access to Critical Breakthrough Products Act originated with NVCA, Aidoc, or their lobbying counsel — a sequence that would be partially visible in comparing bill introduction dates against LDA filing dates. What remains fully hidden is the identity of the VC firms under active consideration for FDA direct contracting relationships, which FDA officials internally developed that proposal and what their prior private-sector affiliations were, and what financial returns the specific VC funds backing Aidoc and 4D Medical stand to realize if Medicare reimbursement is systematically opened to their portfolio products. A FOIA request to FDA for all communications related to the contracting proposal, combined with a full LDA search under NVCA and each named company, and a cross-reference of bill sponsors' campaign finance records against medical AI sector PAC contributions, would close the most significant remaining gaps.